CD44 and ovarian carcinoma: Using a threshold of 25% CD44+/CD24–ve ovarian cancer cells found in ascites, patients with >25% CD44+/CD24−ve were significantly more likely to have recurrence (83 vs. 14%, P=0.003) and had shorter median progression-free survival (6 vs. 18 months, P=0.01) [41].